Kiniksa Pharmaceuticals International Beheer
Beheer criteriumcontroles 4/4
De CEO Kiniksa Pharmaceuticals International is Sanj Patel, benoemd in Jul2015, heeft een ambtstermijn van 9.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.30M, bestaande uit 16.3% salaris en 83.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.38% van de aandelen van het bedrijf, ter waarde $ 38.56M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 7.3 jaar.
Belangrijke informatie
Sanj Patel
Algemeen directeur
US$5.3m
Totale compensatie
| Percentage CEO-salaris | 16.3% |
| Dienstverband CEO | 9.3yrs |
| Eigendom CEO | 2.4% |
| Management gemiddelde ambtstermijn | 3.8yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
Oct 07Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$5m | US$864k | US$14m |
| Sep 30 2023 | n/a | n/a | -US$7m |
| Jun 30 2023 | n/a | n/a | US$231m |
| Mar 31 2023 | n/a | n/a | US$196m |
| Dec 31 2022 | US$6m | US$835k | US$183m |
| Sep 30 2022 | n/a | n/a | US$143m |
| Jun 30 2022 | n/a | n/a | -US$112m |
| Mar 31 2022 | n/a | n/a | -US$134m |
| Dec 31 2021 | US$7m | US$803k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$175m |
| Jun 30 2021 | n/a | n/a | -US$189m |
| Mar 31 2021 | n/a | n/a | -US$184m |
| Dec 31 2020 | US$5m | US$780k | -US$161m |
| Sep 30 2020 | n/a | n/a | -US$140m |
| Jun 30 2020 | n/a | n/a | -US$123m |
| Mar 31 2020 | n/a | n/a | -US$122m |
| Dec 31 2019 | US$5m | US$780k | -US$162m |
| Sep 30 2019 | n/a | n/a | -US$173m |
| Jun 30 2019 | n/a | n/a | -US$170m |
| Mar 31 2019 | n/a | n/a | -US$153m |
| Dec 31 2018 | US$7m | US$740k | -US$103m |
| Sep 30 2018 | n/a | n/a | -US$93m |
| Jun 30 2018 | n/a | n/a | -US$85m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$1m | US$700k | -US$65m |
Compensatie versus markt: De totale vergoeding ($USD 5.30M ) Sanj } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.64M ).
Compensatie versus inkomsten: De vergoeding van Sanj is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Sanj Patel (55 yo)
9.3yrs
Tenure
US$5,297,067
Compensatie
Mr. Sanj K. Patel has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceutica...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.3yrs | US$5.30m | 2.38% $ 38.6m | |
| Senior VP & COO | 2.8yrs | US$1.75m | 0.15% $ 2.5m | |
| Senior VP & Chief Medical Officer | 8.3yrs | US$1.79m | 0.072% $ 1.2m | |
| Senior VP & CFO | 3.9yrs | geen gegevens | 0.032% $ 516.0k | |
| Chief Accounting Officer & Group VP of Finance | 4.8yrs | geen gegevens | 0.037% $ 596.2k | |
| Senior Vice President of Technical Operations | 3.8yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Compliance Officer | 3.6yrs | geen gegevens | geen gegevens | |
| SVP, General Counsel & Secretary | 3.8yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Corporate Affairs | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Regulatory Affairs | 3.9yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Commercial Officer | 2.8yrs | geen gegevens | 0.030% $ 488.4k | |
| Chief Business Officer | less than a year | geen gegevens | geen gegevens |
3.8yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van KNSA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.3yrs | US$5.30m | 2.38% $ 38.6m | |
| Independent Director | 6.8yrs | US$362.66k | 0.013% $ 210.6k | |
| Lead Independent Director | 9.1yrs | US$411.06k | 0.040% $ 642.4k | |
| Independent Director | 7.9yrs | US$380.36k | 0.013% $ 210.6k | |
| Independent Director | 9.1yrs | US$372.55k | 0.013% $ 210.6k | |
| Independent Director | 5.7yrs | US$459.75k | 0.018% $ 289.8k | |
| Independent Director | 4.3yrs | US$365.36k | 0.013% $ 210.6k | |
| Independent Director | 9.1yrs | US$371.96k | 0.012% $ 196.5k | |
| Chairman of Scientific Advisory Board | no data | geen gegevens | 2.05% $ 33.2m | |
| Independent Director | 6.8yrs | US$365.36k | 0.013% $ 210.6k | |
| Director | less than a year | geen gegevens | geen gegevens |
7.3yrs
Gemiddelde duur
55.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van KNSA wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).